239

17 - settembre 2019 - Minuti 21. Niemann T, Kollmann T, Bongartz G. Diagnostic per- formance of lowdose CT for the detection of urolithiasis: a meta-analysis. AJR Am J Roentgenol. 2008; 191(2): 396- 401. 22. Rodger F, Roditi G, Aboumarzouk OM. Diagnostic ac- curacy of low and ultra-low dose CT for identification of urinary tract stones: a systematic review. Urol Int. 2018; 100(4): 375-385. 23. Fulgham PF, Assimos DG, Pearle MS, Preminger GM. Clinical effectiveness protocols for imaging in the manage- ment of ureteral calculous disease: AUA technology asses- sment. J Urol. 2013; 189(4): 1203-1213. 24. Tchey DU, Ha YS, KimWT, Yun SJ, Lee SC, KimWJ. Expectant management of ureter stones: outcome and clini- cal factors of spontaneous passage in a single institution’s ex- perience. Korean J Urol. 2011; 52(12): 847-851. 25. Ahmed AF, Gabr AH, Emara AA, Ali M, Abdel-Aziz AS, Alshahrani S. Factors predicting the spontaneous passage of a ureteric calculus of ≤ 10 mm. Arab J Urol. 2015; 13(2): 84- 90. 26. Coll DM, Varanelli MJ, Smith RC. Relationship of spon- taneous passage of ureteral calculi to stone size and location as revealed by unenhanced helical CT. AJR Am J Roentge- nol. 2002; 178(1): 101-103. 27. Hollingsworth JM, Canales BK, Rogers MA, et al. Al- pha blockers for treatment of ureteric stones: systematic re- view and meta-analysis. BMJ. 2016; 355: i6112. 28. Wang H, Man LB, Huang GL, Li GZ, Wang JW. Com- parative efficacy of tamsulosin versus nifedipine for distal ure- teral calculi: a meta-analysis. Drug Des Devel Ther. 2016; 10: 1257-1265. 29. Pickard R, Starr K, MacLennan G, et al. Medical expul- sive therapy in adults with ureteric colic: a multicentre, randomised, placebo-controlled trial. Lancet. 2015; 386(9991): 341-349. 30. Chua ME, Park JH, Castillo JC, Morales ML Jr. Terpene compound drug as medical expulsive therapy for ureteroli- thiasis: a meta-analysis. Urolithiasis. 2013; 41(2): 143-151. 31. Skolarikos A, Straub M, Knoll T, et al. Metabolic eva- luation and recurrence prevention for urinary stone pa- tients: EAU guidelines. Eur Urol. 2015; 67(4): 750-763. 32. Daudon M, Frochot V, Bazin D, Jungers P. Drug-indu- ced kidney stones and crystalline nephropathy: pathophysio- logy, prevention and treatment. Drugs. 2018; 78(2): 163-201. 33. Bjelakovic G, Gluud LL, Nikolova D, et al. Vitamin D supplementation for prevention of mortality in adults. Co- chrane Database Syst Rev. 2014; (1): CD007470. 34. Izzedine H, Lescure FX, Bonnet F. HIV medication-ba- sed urolithiasis. Clin Kidney J. 2014; 7(2): 121-126. 35. Kahwati LC, Weber RP, Pan H, et al. Vitamin D, cal- cium, or combined supplementation for the primary preven- tion of fractures in communitydwelling adults: evidence re- port and systematic review for the US Preventive Services Task Force. JAMA. 2018; 319(15): 1600-1612. 36. Streeper NM. Asymptomatic renal stones—to treat or not to treat. Curr Urol Rep. 2018; 19(5): 29. 37. Semins MJ, Matlaga BR. Management of urolithiasis in pregnancy. Int J Womens Health. 2013; 5: 599-604. 38. Qaseem A, Dallas P, Forciea MA, Starkey M, Denberg TD. Dietary and pharmacologic management to prevent re- current nephrolithiasis in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2014; 161(9): 659-667. 39. Fink HA, Wilt TJ, Eidman KE, et al. Medical manage- ment to prevent recurrent nephrolithiasis in adults: a syste- matic review for an American College of Physicians clinical guideline [published correction appears in Ann Intern Med. 2013; 159(3): 230-232]. Ann Intern Med. 2013; 158(7): 535-543. 40. Fink HA, Akornor JW, Garimella PS, et al. Diet, fluid, or supplements for secondary prevention of nephrolithiasis: a systematic review and meta-analysis of randomized trials. Eur Urol. 2009; 56(1): 72-80. 41. Phillips R, Hanchanale VS, Myatt A, Somani B, Nabi G, Biyani CS. Citrate salts for preventing and treating calcium containing kidney stones in adults. Cochrane Database Syst Rev. 2015; (10): CD010057. 42. Prezioso D, Strazzullo P, Lotti T, et al. Dietary treatment of urinary risk factors for renal stone formation. A review of CLUWorking Group [published correction appears in Arch Ital Urol Androl. 2016; 88(1): 76]. Arch Ital Urol Androl. 2015; 87(2): 105-120. 43. McDowell SE, Thomas SK, Coleman JJ, Aronson JK, Ferner RE. A practical guide to monitoring for adverse drug reactions during antihypertensive drug therapy [published correction appears in J R Soc Med. 2013; 106(4): 119]. J R Soc Med. 2013; 106(3): 87-95. 44. Goldfarb DS, Coe RL. Prevention of recurrent nephro- lithiasis. Am Fam Physician. 1999; 60(8): 2269-2276. 45. Portis AJ, Sundaram CP. Diagnosis and initial manage- ment of kidney stones. Am Fam Physician. 2001; 63(7): 1329- 1339.